4SC strengthens patent protection for its epigenetic cancer drug in China

17-Aug-2015 - Germany

4SC AG announced that it has further strengthened the patent protection for its epigenetic anti-cancer compound 4SC-202 - a selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China.

The Chinese Intellectual Property Office (SIPO) has granted a patent relating to the tosylate salt of the compound. As this salt has been used in the clinical trials with 4SC-202, this patent provides a further building block in 4SC's global protection strategy for the drug candidate. The patents for 4SC-202 tosylate salt will provide additional protection against potential competitors and thus complements the composition of matter patents for 4SC-202, which so far have been granted in 61 countries, including patents in the major markets USA, Europe, China, Japan, Russia, and India.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...